Ashwani Verma

Q: What is Ashwani Verma's success rate?

Ashwani Verma currently has a success rate of 80.83522327038196.

Q: What is the average return of Ashwani Verma's calls?

Their stock ratings have generated an average return of 9.912084656919973.

UBS | Healthcare

Ashwani Verma is an analyst from UBS specializing in the Healthcare sector. Ranked #2198 out of 4657 analysts, they have issued 45 stock ratings with a success rate of 80.84% and an average return of 9.91%.

Ashwani Verma has a well-established track record, with 45 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 80.84% and an average return of 9.91%, underscoring their expertise and ability to identify winning opportunities for investors.

#2198

Out of 4657

Total Ratings

+80.84%

Success Rate

+9.91%

Average Return

Recent Ratings Analysis

JAZZ

Buy

May 19, 2026

Target

$307.00

Current

$237.45

Performance

0.00%

Ashwani Verma rated JAZZ as Buy on May 19, 2026, setting a price target of 307. Shares have remained stable near 237.45, leaving the 307 target still in play.

CORT

Buy

May 13, 2026

Target

$72.00

Current

$58.22

Performance

2.00%

On May 13, 2026, CORT was given a Buy rating by Ashwani Verma, with a target price of 72. The stock traded sideways with a 2.00% move, keeping the bullish thesis unresolved.

ALKS

Buy

May 06, 2026

Target

$48.00

Current

$37.00

Performance

4.76%

ALKS received a Buy rating from Ashwani Verma on May 06, 2026, aiming for 48. Price action was muted, as shares hovered around 37 despite the bullish outlook.

TEVA

Buy

Apr 30, 2026

Target

$42.00

Current

$34.07

Performance

-2.85%

On Apr 30, 2026, Ashwani Verma published a Buy outlook on TEVA, with a target of 42. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 34.07.

RPRX

Buy

Apr 21, 2026

Target

$57.00

Current

$52.41

Performance

5.92%

Ashwani Verma on Apr 21, 2026 assigned RPRX a Buy rating, with a price target of 57. The Buy call aligned well with market performance, producing a gain of 5.92%.

AMRX

Buy

Apr 17, 2026

Target

$19.00

Current

$11.81

Performance

-15.10%

On Apr 17, 2026, Ashwani Verma reaffirmed AMRX with a Buy rating, targeting 19. Shares slid 15.10% despite the recommendation, highlighting downside risks.

AXSM

Buy

Apr 10, 2026

Target

$259.00

Current

$226.67

Performance

27.26%

AXSM was rated Buy by Ashwani Verma on Apr 10, 2026, with a price objective of 259. A bullish response from the market helped close the gap of 32.33 to the target.

INCY

Hold

Mar 25, 2026

Target

$94.00

Current

$95.60

Performance

3.65%

On Mar 25, 2026, Ashwani Verma initiated coverage on INCY with a Neutral rating and target of 94. The stock’s lack of movement around 95.6 aligned with a cautious approach.

ALVO

Buy

Mar 24, 2026

Target

$6.00

Current

$3.28

Performance

4.79%

Ashwani Verma issued a Buy recommendation for ALVO on Mar 24, 2026, price target set at 6. The target of 6 remains in play, though confirmation will depend on future moves.

CYTK

Hold

Mar 06, 2026

Target

$69.00

Current

$76.45

Performance

26.55%

On Mar 06, 2026, CYTK was evaluated by Ashwani Verma, who gave a Neutral rating and target of 69. Investors who stayed in despite the Hold saw upside of 26.55%.

UTHR

Buy

Mar 05, 2026

Target

$705.00

Current

$566.80

Performance

—

Ashwani Verma rated UTHR as Buy on Mar 05, 2026, setting a price target of 705. Shares have remained stable near 566.8, leaving the 705 target still in play.

HRMY

Hold

Feb 11, 2026

Target

$46.00

Current

$30.44

Performance

-16.81%

On Feb 11, 2026, HRMY was given a Neutral rating by Ashwani Verma, with a target price of 46. The rating provided protection from downside risk as the stock fell to 30.44.

NBIX

Buy

Jan 23, 2026

Target

$178.00

Current

$154.36

Performance

13.35%

NBIX received a Buy rating from Ashwani Verma on Jan 23, 2026, aiming for 178. Momentum has favored the Buy call, with shares climbing from 154.36 to 154.36, rewarding those who trusted the recommendation.

INSM

Buy

Jan 06, 2026

Target

$223.00

Current

$107.41

Performance

-38.65%

On Jan 06, 2026, Ashwani Verma published a Buy outlook on INSM, with a target of 223. Market action contradicted the Buy thesis, as shares slipped to 107.41.

ACAD

Buy

Jan 06, 2026

Target

$40.00

Current

$20.48

Performance

-23.98%

Ashwani Verma on Jan 06, 2026 assigned ACAD a Buy rating, with a price target of 40. The call has struggled to gain traction, with shares losing 23.98%.

LEGN

Buy

Dec 08, 2025

Target

$54.00

Current

$26.94

Performance

3.14%

On Dec 08, 2025, Ashwani Verma reaffirmed LEGN with a Buy rating, targeting 54. Market indecision has kept the 54 target in a holding pattern.

BHVN

Hold

Nov 26, 2025

Target

$26.00

Current

$8.39

Performance

-11.50%

BHVN was rated Neutral by Ashwani Verma on Nov 26, 2025, with a price objective of 26. Investors who stayed cautious avoided some of the 11.50% decline.

ABBV

Hold

Nov 07, 2025

Target

$220.00

Current

$213.86

Performance

-2.42%

On Nov 07, 2025, Ashwani Verma initiated coverage on ABBV with a Neutral rating and target of 220. The stock’s lack of movement around 213.86 aligned with a cautious approach.

EXEL

Hold

Nov 06, 2025

Target

$40.00

Current

$48.67

Performance

19.29%

Ashwani Verma issued a Neutral recommendation for EXEL on Nov 06, 2025, price target set at 40. A neutral call gave way to stronger-than-expected performance, closing in on 40.

AVDL

Hold

Oct 28, 2025

Target

$20.00

Current

$21.64

Performance

16.41%

On Oct 28, 2025, AVDL was evaluated by Ashwani Verma, who gave a Neutral rating and target of 20. Investors who stayed in despite the Hold saw upside of 16.41%.

IMVT

Hold

Jul 28, 2025

Target

$18.00

Current

$26.29

Performance

56.86%

Ashwani Verma rated IMVT as Neutral on Jul 28, 2025, setting a price target of 18. Despite the Hold call, shares climbed 56.86% to 26.29, revealing unexpected momentum.

ACLX

Buy

Dec 10, 2024

Target

$114.00

Current

$115.07

Performance

39.87%

On Dec 10, 2024, ACLX was given a Buy rating by Ashwani Verma, with a target price of 114. The stock rallied 39.87% after the rating, narrowing the gap to the target of 114 and validating the bullish stance.

CHRS

Hold

Aug 16, 2024

Target

$1.50

Current

$1.48

Performance

17.46%

CHRS received a Neutral rating from Ashwani Verma on Aug 16, 2024, aiming for 1.5. Investors saw gains of 17.46% that the cautious stance didn’t fully capture.

ITCI

Hold

Jun 25, 2024

Target

$83.00

Current

$131.87

Performance

82.09%

On Jun 25, 2024, Ashwani Verma published a Neutral outlook on ITCI, with a target of 83. The Hold call missed some of the bullish momentum as shares advanced toward 83.

Frequency Asked Questions

Who is Ashwani Verma?

Ashwani Verma is an analyst from UBS specializing in the Healthcare sector.

What is Ashwani Verma's success rate?

Ashwani Verma currently has a success rate of +80.84%.

How many ratings has Ashwani Verma issued?

Ashwani Verma has issued 45 stock ratings so far.

What is the average return of Ashwani Verma's calls?

Their stock ratings have generated an average return of +9.91%.

What is Ashwani Verma's ranking?

Ashwani Verma is ranked #2198 out of 4657 analysts.

What types of ratings does Ashwani Verma give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Ashwani Verma?

You can follow Ashwani Verma by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Ashwani Verma?

Their latest rating was a Buy on JAZZ issued on 2026-05-19.